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The use of flattening filter free irradiation mode in normo- 
fractionated treatments 
Purpose 
The option to irradiate patients without a flattening filter in the beam path is 
aiming at increased dose rates and reduced beam-on times. Since the 
flattening filter is a source of scatter radiation, its removal has the positive 
side effect of lowering out-of-field doses, which might reduce the risk of 
radiation induced second cancers in peripheral tissue.  
A variety of planning studies has proven that the flattening filter free (FFF) 
mode of a linac allows reducing delivery times in stereotactic treatments with 
high fraction doses. The challenge in FFF treatment planning is, however, 
treatment of large targets due to dose decrease with distance from the 
central beam axis. In addition delivery times are influenced to a larger extent 
by mechanical constraints of the gantry and the multi leaf collimator in 
normo-fractionated treatments with fraction doses around 2 Gy.  
Four studies have been performed at our department comparing the two 
irradiaton modes with (FF) and without flattening filter for normo-
fractionated intensity modulated radiation therapy (IMRT) and volumetric 
modulated arc therapy (VMAT) of prostate cancer1, breast cancer2,3, 
hypopharyngeal cancer4, and childhood ependymoma. The aim of this study 
was to review the data of these studies and to identify general advantages 
and disadvantages of the FFF irradiation mode independent of the target site. 
 
Material and methods 
Planning 
For each of the 4 studies VMAT and IMRT plans had been created for at least 
10 patients in FF and FFF mode with identical dose volume objectives. Target 
sites and prescription doses are listed in table 1. Common measures of plan 
quality were V95%, Conformity Index (CI), and Homogeneity Index (HI) for the 
target volumes. OAR measures were dependent on the target type and 
therefore not suitable as general measures.  
 
 
 
 
 
 
 
 
 
 
Dosimetry 
All treatment plans were verified by a 2D–ionization-chamber-array, and 
delivery times were measured from first beam on to last beam off. Out-of-
field doses were determined with an ionization chamber at 31 cm from 
isocenter. The radiation induced second cancer risk is proportional to dose up 
to around 2 Gy. The measurement setup is shown in figure 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Statistical evaluation 
The data of the common measures of the four studies were pooled for 
statistical evaluation. To allow comparison of the measures despite 
differences in prescription dose, the data were normalized to the value of the 
measure in FF mode. Differences between the irradiation modes were 
calculated in percent of the value in FF mode.   
The two sided Wilcoxon signed rank test was used to detect relevant 
differences with a significance level of a = 0.05. Due to multiple pairwise 
comparisons, the Bonferroni-Holm method for multiple testing was applied 
to control the maximum experimentwise error rate by adjusting the level of 
significance: All hypotheses are sorted in order of smallest p-value to largest. 
The m-th hypothesis out of n is rejected if pm ≤ a / (n+1-m) = an,m. The 
process is stopped when one hypothesis is accepted.  
 
Results 
All plans passed the dosimetrical verification. The results of the statistical 
evaluation are shown in figure 2 and table 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Statistically significant differences were found for out-of-field dose, target 
V95% and HI, all of them in favour of FFF. Differences of target V95% and HI 
were, however, below 2% and are therefore considered of limited clinical 
relevance.  
The out-of-field dose as a measure of radiation induced second cancer risk in 
peripheral organs was substantially reduced  in FFF mode. The reduction 
amounted to 20% averaged over all cases. 
  
Conclusion 
The only statistically significant and clinically relevant advantage of the FFF 
mode was a reduction in dose to peripheral organs, corresponding to a mean 
reduction of 20% in radiation induced second cancer risk in these organs. 
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Table 1: Target sites and prescription doses.  
PTV: Planning Target Volume,  
SIB: Simultaneous Integrated Boost volume 
Target Prescription dose  # fractions 
Hypopharynx PTV / SIB 54 Gy / 66 Gy 30 
Breast PTV / SIB 50.4 Gy / 63 Gy 28 
Prostate PTV / SIB 62.5 Gy / 72.6 Gy 33 
Ependymoma PTV 50.4 Gy 28 
Figure 1: Measurement setup 
Table 2: Relative differences between FFF und FF irradiation mode for the 5 
common measures M in % of the reference value M(FF) (mean over all cases). 
Bold values indicate statistically significant improvements of FFF versus FF. 
Measure M 
(M(FFF)-M(FF)) / 
M(FF) 
 p a n,m 
Out-of-field dose - 20.1 % 0.000 0.0100 
Target V95% 0.3 % 0.000 0.0125 
Target HI - 1.8 % 0.002 0.0167 
Target CI 1.8  % 0.043 0.0250 
Delivery time - 1.2 % 0.156 0.0500 
Figure 2: Graphical illustration of the relative differences (mean value and 
standard deviation over all cases) between FFF und FF for the five common 
measures M in % of the reference value M(FF).  
